Jove
Visualize
Contact Us

Related Experiment Videos

Cancer-induced retinal hypersensitivity

C E Thirkill1

  • 1University of California, Sacramento 95816, USA.

British Journal of Biomedical Science
|September 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Paraneoplastic vitelliform retinopathy secondary to metastatic melanoma.

Klinische Monatsblatter fur Augenheilkunde·2015
Same author

An unusual case of melanoma-associated retinopathy.

Ocular immunology and inflammation·2012
Same author

Immune-mediated paraneoplasia.

British journal of biomedical science·2007
Same author

Autoimmune retinopathy associated with intravesical BCG therapy.

The British journal of ophthalmology·2005
Same author

Incidence of antiretinal antibodies in melanoma: screening of 77 serum samples from 51 patients with American Joint Committee on Cancer stage I-IV.

The British journal of dermatology·2005
Same author

Cachexia and poor night vision.

Lancet (London, England)·2004
Same journal

Artificial intelligence approaches in biological age prediction: current status and challenges.

British journal of biomedical science·2026
Same journal

Challenges and emerging strategies for genome-wide evaluation of loss of imprinting in cancer.

British journal of biomedical science·2026
Same journal

Application of non-invasive preimplantation genetic screening for aneuploidy through spent embryo culture media analysis at 48 and 54 hours after embryo cleavage.

British journal of biomedical science·2026
Same journal

Training on PD-L1 scoring in non-small cell lung cancer with high intra- and inter-reader agreement: results of a worldwide microscopic/digital image-based training of 751 pathologists.

British journal of biomedical science·2026
Same journal

Performance of a quality control center supporting national antimicrobial resistance surveillance.

British journal of biomedical science·2026
Same journal

The Molecular Pathology of Non-Malignant Haematological Disease.

British journal of biomedical science·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Early cancer signs include neurological issues and unexplained weight loss. Detecting specific autoantibodies can identify paraneoplastic syndromes, sometimes before the tumor is found.

Area of Science:

  • Oncology
  • Immunology
  • Neurology

Background:

  • Paraneoplastic syndromes are often the first indicators of cancer, manifesting as neurological dysfunction or rapid weight loss.
  • These syndromes arise from the body's immune response to cancer, leading to autoimmune reactions against normal tissues.
  • Specific examples include Lambert-Eaton myasthenic syndrome (LEMS), paraneoplastic cerebellar degenerations (PCD), and cancer-associated retinopathy (CAR).

Purpose of the Study:

  • To explore the earliest manifestations of cancer, focusing on paraneoplastic syndromes.
  • To investigate the immunologic basis of paraneoplastic syndromes and their association with specific cancers.
  • To highlight the diagnostic utility of autoantibody detection in identifying paraneoplastic syndromes.

Main Methods:

Related Experiment Videos

  • Review of clinical manifestations of paraneoplastic syndromes.
  • Immunological identification of autoantibodies targeting specific proteins in LEMS, PCD, and CAR.
  • Correlation of autoantibody findings with underlying neoplastic disease.

Main Results:

  • Paraneoplastic syndromes, including neurological deficits and weight loss, serve as early cancer indicators.
  • Autoantibodies against specific proteins (e.g., brain, muscle, ocular antigens) are key biomarkers for PCD, LEMS, and CAR.
  • Commercial blood tests for these autoantibodies can detect paraneoplastic syndromes, aiding in early cancer diagnosis.

Conclusions:

  • Paraneoplastic syndromes represent a crucial window into early cancer detection and the underlying autoimmune mechanisms.
  • The identification of specific autoantibodies has revolutionized the diagnosis of these rare but significant conditions.
  • Further research into the immunologic connection between cancer and paraneoplastic syndromes is warranted for improved patient outcomes.